Credit Suisse Ag Verve Therapeutics, Inc. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
A detailed history of Credit Suisse Ag transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 65,742 shares of VERV stock, worth $731,708. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,742
Previous 62,853
4.6%
Holding current value
$731,708
Previous $876,000
0.34%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding VERV
# of Institutions
26Shares Held
8.54MCall Options Held
31.4KPut Options Held
122K-
Black Rock Inc. New York, NY6.62MShares$73.7 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL1.32MShares$14.6 Million0.0% of portfolio
-
Wade G W & Inc Wellesley, MA260KShares$2.89 Million0.12% of portfolio
-
Xtx Topco LTD London, X0125KShares$1.39 Million0.08% of portfolio
-
Greenland Capital Management LP New York, NY49.5KShares$551,0010.06% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $667M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...